TNDM — Tandem Diabetes Care Income Statement
0.000.00%
Last trade - 00:00- $1.20bn
- $1.11bn
- $940.20m
- 70
- 40
- 44
- 50
Annual income statement for Tandem Diabetes Care, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 499 | 703 | 801 | 748 | 940 |
| Cost of Revenue | |||||
| Gross Profit | 261 | 376 | 413 | 368 | 490 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 507 | 680 | 894 | 981 | 1,041 |
| Operating Profit | -7.96 | 22.7 | -92.8 | -233 | -100 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -36.3 | 15.9 | -92.9 | -220 | -91.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.4 | 15.6 | -94.6 | -223 | -96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.4 | 15.6 | -94.6 | -223 | -96 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.4 | 15.6 | -94.6 | -223 | -96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.564 | 0.242 | -1.42 | -2.1 | -1.45 |